GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (LTS:0A8I) » Definitions » Inventories, Other

Genprex (LTS:0A8I) Inventories, Other : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genprex Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Genprex's other inventories for the quarter that ended in Sep. 2024 was $0.00 Mil.


Genprex Inventories, Other Historical Data

The historical data trend for Genprex's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Inventories, Other Chart

Genprex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only - - - - -

Genprex Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genprex Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Genprex Business Description

Traded in Other Exchanges
Address
3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex Headlines

No Headlines